Clinical Trials
54 trialsCombination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
eVOLVE-02
AstraZeneca
SAFE ESO
University Hospital, Clermont-Ferrand
ANCRE
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Fudan University
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
BeOne Medicines
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital of Zunyi Medical University
INS-ESCC-CT
Sichuan University
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Tianjin Medical University Cancer Institute and Hospital
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
The Affiliated Hospital of Putian University
SCR-ESCC-01
Shanghai Chest Hospital
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
VA Office of Research and Development
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
Anhui Provincial Hospital
ESCC
Fujian Medical University Union Hospital
BRIGHT-ESCC
National Taiwan University Hospital
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Zhejiang Cancer Hospital
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Tongji Hospital
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
The First Affiliated Hospital of Zhengzhou University
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Shanghai Zhongshan Hospital
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
Sichuan University
SG-ESCC
National Taiwan University Hospital
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Shanghai Chest Hospital
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Peking University
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
Sichuan University
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Tang-Du Hospital
RICE
Fujian Medical University Union Hospital
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
EC-CRT-007
Sun Yat-sen University
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Zhejiang Cancer Hospital
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Affiliated Hospital of Nantong University
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Ruijin Hospital
NTNC
Hebei Medical University Fourth Hospital
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
Tang-Du Hospital